PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis
William J. Sandborn(University of San Diego), Suneel Gupta(Canberra Hospital), Richard Shames, Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Rish K. Pai(University Hospitals of Cleveland), Bittoo Kanwar, Geert D’Haens(Amsterdam University Medical Centers), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Brian Bressler(University of British Columbia), Scott Lee(University of Washington), Raj Bhandari(Delta Air Lines (United States)), Nishit B. Modi(Protagonist Therapeutics (United States)), David Y. Liu(Protagonist Therapeutics (United States)), Larry Mattheakis(Quantum Devices (United States)), David Pugatch
Cited by 37
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k